vs
Fabrinet（FN）与Medpace Holdings, Inc.（MEDP）财务数据对比。点击上方公司名可切换其他公司
Fabrinet的季度营收约是Medpace Holdings, Inc.的1.6倍（$1.1B vs $708.5M），Medpace Holdings, Inc.净利率更高（19.1% vs 9.9%，领先9.1%），Fabrinet同比增速更快（35.9% vs 32.0%），Medpace Holdings, Inc.自由现金流更多（$188.1M vs $-5.3M），过去两年Fabrinet的营收复合增速更高（24.4% vs 17.7%）
Fabrinet（股票代码FN）为标普中型股400指数成分股。该指数由标普道琼斯指数公司维护，覆盖400家以美企为主的中等市值企业，若成分企业存在多类流通股，指数的成分股总量有时会超过400只。
Medpace Holdings, Inc.是总部位于美国俄亥俄州辛辛那提的全球性临床研究机构（CRO），现有员工约6000人。公司采用全服务运营模式，可提供全球中心实验室、影像核心实验室、生物分析实验室服务，且在总部临床研究园区内设有I期临床试验单元。
FN vs MEDP — 直观对比
营收规模更大
FN
是对方的1.6倍
$708.5M
营收增速更快
FN
高出3.9%
32.0%
净利率更高
MEDP
高出9.1%
9.9%
自由现金流更多
MEDP
多$193.5M
$-5.3M
两年增速更快
FN
近两年复合增速
17.7%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $708.5M |
| 净利润 | $112.6M | $135.1M |
| 毛利率 | 12.2% | — |
| 营业利润率 | 10.1% | 21.6% |
| 净利率 | 9.9% | 19.1% |
| 营收同比 | 35.9% | 32.0% |
| 净利润同比 | 30.0% | 15.5% |
| 每股收益（稀释后） | $3.11 | $4.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FNMEDP
| Q4 25 | $1.1B | $708.5M | ||
| Q3 25 | $978.1M | $659.9M | ||
| Q2 25 | $909.7M | $603.3M | ||
| Q1 25 | $871.8M | $558.6M | ||
| Q4 24 | $833.6M | $536.6M | ||
| Q3 24 | $804.2M | $533.3M | ||
| Q2 24 | $753.3M | $528.1M | ||
| Q1 24 | $731.5M | $511.0M |
净利润FNMEDP
| Q4 25 | $112.6M | $135.1M | ||
| Q3 25 | $95.9M | $111.1M | ||
| Q2 25 | $87.2M | $90.3M | ||
| Q1 25 | $81.3M | $114.6M | ||
| Q4 24 | $86.6M | $117.0M | ||
| Q3 24 | $77.4M | $96.4M | ||
| Q2 24 | $81.1M | $88.4M | ||
| Q1 24 | $80.9M | $102.6M |
毛利率FNMEDP
| Q4 25 | 12.2% | — | ||
| Q3 25 | 11.9% | — | ||
| Q2 25 | 12.2% | — | ||
| Q1 25 | 11.7% | — | ||
| Q4 24 | 12.1% | — | ||
| Q3 24 | 12.3% | — | ||
| Q2 24 | 12.3% | — | ||
| Q1 24 | 12.4% | — |
营业利润率FNMEDP
| Q4 25 | 10.1% | 21.6% | ||
| Q3 25 | 9.6% | 21.5% | ||
| Q2 25 | 9.8% | 20.9% | ||
| Q1 25 | 9.0% | 20.3% | ||
| Q4 24 | 9.5% | 23.4% | ||
| Q3 24 | 9.6% | 21.1% | ||
| Q2 24 | 9.7% | 19.9% | ||
| Q1 24 | 9.7% | 20.4% |
净利率FNMEDP
| Q4 25 | 9.9% | 19.1% | ||
| Q3 25 | 9.8% | 16.8% | ||
| Q2 25 | 9.6% | 15.0% | ||
| Q1 25 | 9.3% | 20.5% | ||
| Q4 24 | 10.4% | 21.8% | ||
| Q3 24 | 9.6% | 18.1% | ||
| Q2 24 | 10.8% | 16.7% | ||
| Q1 24 | 11.1% | 20.1% |
每股收益（稀释后）FNMEDP
| Q4 25 | $3.11 | $4.65 | ||
| Q3 25 | $2.66 | $3.86 | ||
| Q2 25 | $2.41 | $3.10 | ||
| Q1 25 | $2.25 | $3.67 | ||
| Q4 24 | $2.38 | $3.67 | ||
| Q3 24 | $2.13 | $3.01 | ||
| Q2 24 | $2.22 | $2.75 | ||
| Q1 24 | $2.21 | $3.20 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $960.8M | $497.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.2B | $459.1M |
| 总资产 | $3.3B | $2.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FNMEDP
| Q4 25 | $960.8M | $497.0M | ||
| Q3 25 | $968.8M | $285.4M | ||
| Q2 25 | $934.2M | $46.3M | ||
| Q1 25 | $950.7M | $441.4M | ||
| Q4 24 | $934.6M | $669.4M | ||
| Q3 24 | $908.9M | $656.9M | ||
| Q2 24 | $858.6M | $510.9M | ||
| Q1 24 | $794.0M | $407.0M |
股东权益FNMEDP
| Q4 25 | $2.2B | $459.1M | ||
| Q3 25 | $2.1B | $293.6M | ||
| Q2 25 | $2.0B | $172.4M | ||
| Q1 25 | $1.9B | $593.6M | ||
| Q4 24 | $1.8B | $825.5M | ||
| Q3 24 | $1.8B | $881.4M | ||
| Q2 24 | $1.7B | $763.6M | ||
| Q1 24 | $1.7B | $671.5M |
总资产FNMEDP
| Q4 25 | $3.3B | $2.0B | ||
| Q3 25 | $3.0B | $1.8B | ||
| Q2 25 | $2.8B | $1.6B | ||
| Q1 25 | $2.6B | $1.9B | ||
| Q4 24 | $2.5B | $2.1B | ||
| Q3 24 | $2.4B | $2.1B | ||
| Q2 24 | $2.3B | $1.9B | ||
| Q1 24 | $2.2B | $1.8B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $46.3M | $192.7M |
| 自由现金流经营现金流 - 资本支出 | $-5.3M | $188.1M |
| 自由现金流率自由现金流/营收 | -0.5% | 26.6% |
| 资本支出强度资本支出/营收 | 4.6% | 0.6% |
| 现金转化率经营现金流/净利润 | 0.41× | 1.43× |
| 过去12个月自由现金流最近4个季度 | $102.3M | $681.9M |
8季度趋势，按日历期对齐
经营现金流FNMEDP
| Q4 25 | $46.3M | $192.7M | ||
| Q3 25 | $102.6M | $246.2M | ||
| Q2 25 | $55.1M | $148.5M | ||
| Q1 25 | $74.2M | $125.8M | ||
| Q4 24 | $115.9M | $190.7M | ||
| Q3 24 | $83.2M | $149.1M | ||
| Q2 24 | $83.1M | $116.4M | ||
| Q1 24 | $100.9M | $152.7M |
自由现金流FNMEDP
| Q4 25 | $-5.3M | $188.1M | ||
| Q3 25 | $57.3M | $235.5M | ||
| Q2 25 | $4.7M | $142.4M | ||
| Q1 25 | $45.7M | $115.8M | ||
| Q4 24 | $94.0M | $183.0M | ||
| Q3 24 | $62.9M | $138.5M | ||
| Q2 24 | $70.4M | $103.5M | ||
| Q1 24 | $87.3M | $147.2M |
自由现金流率FNMEDP
| Q4 25 | -0.5% | 26.6% | ||
| Q3 25 | 5.9% | 35.7% | ||
| Q2 25 | 0.5% | 23.6% | ||
| Q1 25 | 5.2% | 20.7% | ||
| Q4 24 | 11.3% | 34.1% | ||
| Q3 24 | 7.8% | 26.0% | ||
| Q2 24 | 9.3% | 19.6% | ||
| Q1 24 | 11.9% | 28.8% |
资本支出强度FNMEDP
| Q4 25 | 4.6% | 0.6% | ||
| Q3 25 | 4.6% | 1.6% | ||
| Q2 25 | 5.5% | 1.0% | ||
| Q1 25 | 3.3% | 1.8% | ||
| Q4 24 | 2.6% | 1.4% | ||
| Q3 24 | 2.5% | 2.0% | ||
| Q2 24 | 1.7% | 2.4% | ||
| Q1 24 | 1.9% | 1.1% |
现金转化率FNMEDP
| Q4 25 | 0.41× | 1.43× | ||
| Q3 25 | 1.07× | 2.22× | ||
| Q2 25 | 0.63× | 1.65× | ||
| Q1 25 | 0.91× | 1.10× | ||
| Q4 24 | 1.34× | 1.63× | ||
| Q3 24 | 1.07× | 1.55× | ||
| Q2 24 | 1.02× | 1.32× | ||
| Q1 24 | 1.25× | 1.49× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FN
| Optical Communications | $832.6M | 73% |
| Non Optical Communications | $300.3M | 27% |
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
